All News

Refunds will be offered to plan sponsors if a patient discontinues a preferred anti-inflammatory drug within 90 days.

Exondys 51 granted accelerated approval to treat Duchenne muscular dystrophy.

Exondys 51 is the first drug approved by the FDA to treat Duchenne muscular dystrophy.

Focus on the early stages of chronic obstructive pulmonary disease could prevent long-term lung function loss.

Savings program offers $0 co-pays and customer support on antiepileptic treatment.

Approximately 4.3 million people reported nonmedical use of prescription pain killers in 2014.

Top news of the day from across the healthcare landscape.

Drugs targeting allosteric binding sites may prevent side effects associated with heart medications.

Neutron crystallography may lead to new structure-based drug design.

Top news of the day from across the health care landscape.

Nasal cavity hydration may be an important factor preventing nosebleeds in patients with hemorrhagic telangiectasia.

New strategy helps slow kidney disease progression that can occur in diabetes.

New insights pave the way for future treatment developments of pancreatic ductal adenocarcinoma.

HIV Test-and-Treat initiates antiretroviral therapy promptly, but may be too expensive to employ nationwide.

The FDA has just approved Bayer's levonorgestrel-releasing intrauterine system (Kyleena), a long-term, progestin-containing intrauterine device (IUD) that will be available by prescription in October 2016.

In our view, the recent focus and attention being paid to drug prices has the potential to bear positive results.

The Generic Pharmaceutical Association (GPhA) is the presenting sponsor of this event which supports Hope for Henry, a Washington, DC area nonprofit that provides exceptional quality-of-life-saving care for children fighting cancer and other serious illnesses at Children's National, MedStar Georgetown University Hospital and Sinai Hospital of Baltimore.

With the advent of massive open online courses, one university has made MBA content available to all.

Since dabigatran's introduction to the US market in 2010, the medical community hasn't reached a clear consensus on the terminology for its drug class.

Although these interactions pose a threat to patients, pharmacists can play a large role in minimizing them.

The Pharmacy Future Leaders Podcast returns to the Pharmacy Podcast Network with new host Tony Guerra, PharmD.

Surprisingly, Americans rank cancer high above infectious diseases like the Zika virus as their most significant health care concern.

Top articles of the week from The American Journal of Pharmacy Benefits.

Top news of the week in oncology, and cancer drug development.

Final requirements issued that address the health of safety of Medicare and Medicaid recipients during an emergency.

New mouse study suggests that exposure to endocrine disrupting chemicals may cause resistance to tamoxifen therapy in some breast cancers.

Family farms disappear as globalization pushes farming to consolidation and specialization. Are there parallels with the family pharmacy?

Ocrelizumab (Ocrevus) may improve treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.

Nutra Pharma and Omnia Biologics will partner to create pediatric multiple sclerosis treatment derived from cobra venom.

Novel drug combined with gemcitabine chemotherapy shows promise